Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D.

We love to hear from our listeners. Send us a message. Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space and the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity. Access th...